HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing immunotherapies based on a proprietary arenavirus platform. The platform works by engineering arenaviruses to carry disease-specific antigens into the body, where they infect antigen-presenting cells that then activate CD8+ T cells to target and destroy cancer cells or pathogen-infected cells. HOOKIPA has no approved products and no commercial revenue; the company is funded through collaboration and licensing deals, primarily with Gilead Sciences. The lead program is HB-700, which targets five common KRAS mutations found across pancreatic, colorectal, and lung cancers, and is Phase 1-ready following IND clearance from the FDA. The prior lead oncology program, eseba-vec (HB-200), targeting HPV16+ head and neck cancers, was paused in late 2024 as part of a restructuring, and HOOKIPA is now seeking a partner to advance it. Under the Gilead collaboration, HOOKIPA is also advancing HB-400 (Hepatitis B) and HB-500 (HIV) through Phase 1b trials, with Gilead holding an option to take back development rights for the HIV program. A major restructuring in November 2024 cut headcount by roughly 80% and closed labs in Vienna, narrowing HOOKIPA's focus sharply to HB-700 and the Gilead-partnered programs. HOOKIPA relies on contract manufacturers and has no internal manufacturing facilities.